Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow PODD
Insulet Corporation 10-K filed Feb 18, 2026
What changed
Item 1, Business, against the 10-K filed Feb 21, 2025: 8 added · 25 removed · 56 modified; 5 with only figures updated
-
Modified · Market Opportunity: Management of Diabetes
•Type 2 diabetes, the more common form, is characterized by the body’s inability to either properly utilize insulin or produce enough insulin. Historically, type 2 diabetes has occurred in later adulthood, but its incidence is increasing among
the younger populationchildren and young adults, due primarily to increasing obesity. Initially, many people with type 2 diabetes attempt to manage their diabetes with improvements in diet, exercise, and/or medications, both oral and injectable, including SGLT2 inhibitors and GLP-1 drugs. As their diabetes advances, some individuals progress to multiple drug therapies, which often include insulin therapy. People with type 2 diabetes who take insulin either require intensive insulin therapy (typically multiple injections of insulin per day) or basal (long-acting) insulin (typically a single injection daily or weekly). We estimate that approximately 6 million people haveinsulin-intensiveinsulin-requiring type 2 diabetes in the countries we currently serve and another 3 million people with type 2 diabetes in the United States require onlylong-actingbasal insulin.
88 more changes in this Item, word by word, in Powerpack.
Powerpack